ENTA250117P2500
- 0.00
- 0.000.00%
Enanta Pharmaceuticals Newsroom
Sector Update: Health Care Stocks Mixed Tuesday Afternoon
Top Midday Decliners
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Enanta Pharmaceuticals to Appeal Court Ruling on Patent Infringement Case Against Pfizer
Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer
Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned
Enanta Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $18
Enanta Pharma Analyst Ratings
Promising Virology Outcomes Boost Buy Rating for Enanta Pharmaceuticals Despite Symptom Assessment Concerns
Enanta Pharmaceuticals to Appeal Ruling Related to '953 Patent Infringement Lawsuit
Enanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy Buchanan
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $20
Insider Sale: Chief Product Strategy Officer of $ENTA (ENTA) Sells 2,283 Shares
Oppenheimer Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating, Maintains Target Price $14
Enanta Pharmaceuticals (ENTA) Gets a Hold From Oppenheimer
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $21
Enanta Pharmaceuticals' RSV Platform Advances: Buy Rating Affirmed on Promising Clinical Data
Express News | Enanta Pharmaceuticals Inc - Zelicapavir Well-Tolerated With Favorable Safety Profile
Express News | Enanta Pharmaceuticals Inc - Antiviral Effect Observed With 1.4 Log Viral Load Decline in Part 2